COMPASS Pathways plc

NasdaqGS CMPS

COMPASS Pathways plc Shareholders' Equity for the year ending December 31, 2023: USD 225.74 M

COMPASS Pathways plc Shareholders' Equity is USD 225.74 M for the year ending December 31, 2023, a 24.53% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

COMPASS Pathways plc Shareholders' Equity for the year ending December 31, 2022 was USD 181.28 M, a -36.26% change year over year.
COMPASS Pathways plc Shareholders' Equity for the year ending December 31, 2021 was USD 284.41 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: CMPS

COMPASS Pathways plc

CEO	Mr. Kabir Kumar Nath M.A., M.B.A.
IPO Date	Sept. 18, 2020
Location	United Kingdom
Headquarters	33 Broadwick Street
Employees	186
Sector	Healthcare
Industries Mental Health Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years